Gabapentin
产品说明书
 |
同义名 : | CI-945 |
| CAS号 : | 60142-96-3 | |
| 货号 : | A262003 | |
| 分子式 : | C9H17NO2 | |
| 纯度 : | 98% | |
| 分子量 : | 171.23 | |
| MDL号 : | MFCD00865286 | |
| 存储条件： |
Pure form Keep in dark place,Sealed in dry,Room Temperature In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 1 mg/mL(5.84 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO H2O: 50 mg/mL(291.99 mM)，配合低频超声助溶 |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Gabapentin (GBP) is an analog of GABA, it does not bind to GABAA or GABAB receptors, but it can increase GABA and can decrease glutamate concentrations. One imaging study has reported that gabapentin (1200 and 2400 mg) significantly (and rapidly) increased measurable concentrations of brain gamma-aminobutryric acid (GABA)[3]. In vivo, once daily treatment with the anti-epileptic and neuropathic pain medication, gabapentin, at low dosage (50 mg/kg) mitigates experimentally induced autonomic dysreflexia (AD) soon after injections, likely by impeding glutamatergic signaling. In addition distinct mechanisms of action for acute GBP to mitigate induced AD whereas chronic GBP increases non-induced AD frequencies[4]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT00967707 | Post-traumatic Neuropathic Pai... 展开 >>n 收起 << | Phase 2 | Completed | - | Sweden ... 展开 >> Multidisciplinary Pain Centre, Uppsala University Hospital Uppsala, Sweden, 75185 收起 << |
| NCT01177514 | Pain After Photorefractive Ker... 展开 >>atectomy 收起 << | Phase 4 | Completed | - | Mexico ... 展开 >> Codet Vision Institute Tijuana, Baja California, Mexico, 22320 收起 << |
| NCT00934193 | Post-thoracotomy Pain | Phase 3 | Withdrawn | - | - |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
5.84mL 1.17mL 0.58mL |
29.20mL 5.84mL 2.92mL |
58.40mL 11.68mL 5.84mL |
| 参考文献 |
|---|